Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.

摘要: A joint World Health Organization/National Institute of Allergy and Infectious Diseases 2-day meeting in Bethesda Maryland 1996 reviewed the current status development respiratory syncytial virus (RSV) parainfluenza type 3 (PIV3) vaccines. This report reviews progress vaccines for PIV3 (bovine live attenuated cold-adapted human vaccinia recombinants subunit vaccines) RSV (cold-adapted mutants antigenic subgroup B recombinants). The recent recovery infectious from cDNA certain non-segmented negative-strand RNA viruses represents first available method direct genetic manipulation. New "rescue" technology raises possibility use on as expression vectors foreign genes has been used to investigate basic features viral molecular biology. engineered will be an important component future studies biology pathogenesis vaccine viruses. These seem highly tolerant engineering insertion sequences.